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1. Introduction 
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the 
gastrointestinal tract. These are rare tumors representing approximately 0.1-3.0% of all 
gastrointestinal cancers and approximately 5% of all soft tissue sarcomas (Reid et al., 2005; 
Fletcher et al., 2002). Due to their similar appearance by light microscopy, GISTs were 
previously thought to be smooth muscle neoplasms, and most were classified as 
leiomyosarcoma (Reid et al, 2005). (Table 1) The precise cellular origin of these tumors has 
been proposed to be the interstitial cell of Cajal, an interstitial pacemaker cell (Connolly et 
al., 2003). 
It is important to differentiate between GISTs, which constitute approximately 80% of 
gastrointestinal mesenchymal tumors, and the less common gastrointestinal non-epithelial 
neoplasms, leiomyoma, leiomyosarcoma (10-15% of mesenchymal tumors), schwannomas 
(5%), and other malignant disorders. 
Nearly all GISTs (90-100%) display strong immunohistochemical staining for kit (CD 117), 
and this can be used in their differential diagnosis and positive identification. Smooth 
muscle neoplasms, and neurogenic tumours (schwannoma) typically do not show a positive 
expression of CD117, but can be distinguished from GISTs by histological and clinical 
means. It is recommended that CD117 immunostaining should be performed to facilitate the 
diagnosis of GISTs for spindle cell or epithelioid tumors arising the gastrointestinal tract. 
Diagnosis, however, should not be based purely on CD117 expression. The diagnosis of 
CD117 negative GISTs should only be made with extreme care. If there is evidence of 
desmin or S-100 expression and the tumor is not associated with the gut wall then a 
diagnosis of a kit negative GIST should not be made. 
Mutations of kit are common in malignant GISTs and lead to constitutional activation of 
tyrosine kinase function, which causes cellular proliferation and resistance to apoptosis. It is 
also important the stain for the myeloid stem cell antigen CD 34 in 53% to 71% of cases. 
(Connolly et al., 2003; De Matteo et al., 2000; Saund et al., 2004, Yamamoto et al., 2004). 
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  CD 117  CD 34 SMA Desmin S-100 
GIST + 
Around
95% 
+ 
60-70%
+ 
30-40%
 
Very rare
+ 
5% 
Smooth 
Muscle 
Tumor 
 
- 
+ 
10-15%
 
+ 
 
+ 
 
Rare 
 Schwannoma - + - - + 
Table 1. Immunohistochemical schema for the differential diagnosis of spindle cell tumors of 
the gastrointestinal tract. (Reid et al., 2005). 
Approximately, 30% of GISTs are malignant. The principal sites of metastasis are the liver 
and the peritoneal cavity. Rarely, GISTs metastasise to other sites such as the lymph nodes, 
lung, bone (Reid et al., 2005), and muscle (Pasku et al., 2008).  
The most frequent anatomic sites of tumor origin are the stomach (70%), the small intestine 
(20-30%), esophagus, colon and rectum (10%) (Reid et al., 2005). (Table 2). 
 
Site Percentage 
Stomach 60-70% 
Small intestine 20-30% 
Oesophagus, mesentery, omentum, colon and rectum 10% 
Table 2. Site of GISTs. (Reid et al., 2005) 
They are rare before the age of 40 years and very rare in children, with a median age of 50-60 
years. Some data show a slight male predominance. (Reid et al., 2005). 
The symptoms (Table 3) (Nickl et al., 2004; Reid et al., 2005, Saund et al., 2004) of GISTs are 
non-especific and depend on the size and location of the lesion. Small GISTs (2cm or less) are 
usually asymptomatic and are detected during investigations or surgical procedures of 
unrelated causes. The vast majority of these are low-risk for malignancy. The most common 
symptom is gastrointestinal bleeding which is present in approximately 50% of patients. 
Systemic symptoms such as fever, night sweats, and weight loss are common in GISTs and 
very rare in other sarcomas. Patients with larger tumors may experience abdominal discomfort 
or develop a palpable mass. Up to 25% of patients present with acute haemorrhage into the 
intestinal tract or peritoneal cavity from tumor rupture. Symptomatic oesophageal GISTs 
typically present with dysphagia, while gastric and small intestinal GISTs often present with 
vage symptoms leading to their eventual detection by gastroscopy or radiology. Most 
duodenal GISTs occur in the second part of the duodenum where they push or infiltrate into 
the pancreas. Colorectal GISTs may manifest with pain and gastrointestinal obstruction, and 
lower intestinal bleeding. Rectal tumors are usually deep intramural tumors. 
 
Symptoms Incidence 
Abdominal pain 20-50% 
Gastrointestinal bleeeding 50% 
Gastrointestinal obstruction 10-30% 
Asymptomatic 20% 
Table 3. Symptoms of GIST at diagnosis. (Reid et al., 2005) 
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The pathogenesis of GISTs has been established by the observation that kit is highly 
expressed and mutated in almost all tumors (Taniguchi et al., 1999). The use of antibodies to 
kit, as part of an immunohistochemical panel and in combination with traditional 
histological and clinical examinations, means that it is possible to distinguish clearly GISTs 
from other gastrointestinal tract tumours. In addition, the tyrosine kinase inhibitor imatinib 
mesilate (Gleevec™) represents a major breakthrough in the treatment of GISTs, as it has 
significant antitumour activity in these neoplasms, which are generally resistant to cytotoxic 
chemotherapy (Zalupski et al. 1991; Ronellenfitsch et al., 2008). A second targeted tyrosine 
kinase inhibitor, sunitinib malate (Sutent™), has been approved for the treatment of imatinib-
resistant gastrointestinal stromal tumors. (Raut et al., 2007).  
Surgical resection is the principal treatment for GISTs. Evaluation of the resecability of a 
GIST is determined by the surgeon and depends on the stage and the individual patient’s 
fitness for surgery. The primary goal of surgery is complete resection of the disease with 
avoidance of tumor rupture. Care is necessary as GISTs are often soft and fragile, and tumor 
rupture may seed implants in the peritonel cavity and liver. A wide local resection with 
macroscopic removal of the entire tumor to achieve microscopic clearance is recommended. 
An adequate cancer margin is considered to be 2cm (Reid et al.,2005) but this is not always 
possible. 
It is recommended that all patients should be followed up. Observation is the current 
standard of care after complete resection of a primary tumor. Following initial assessment, 
high risk tumors should have computed tomography (CT) every 6 months for 3 years. 
However, in all cases, if symptoms become evident an early CT may be appropriate. 
Regardless of risk, clinic review should be indefinite, as these tumors may recur several 
years after apparently curative resection. 
There was no currently accepted adjuvant therapy regimen before Gleevec™ was approved. 
Gleevec™ is generally well tolerated at doses up to 800mg/day. Toxicities include nausea 
and vomiting, diarrhoea, myalgia, skin rash and occasional neutropenia (Table 4). Although 
frequent, these toxicities rarely require withdrawal of Gleevec™. 
 
Blood and lymphatic system disorders Neutropenia, thrombocytopenia, anaemia 
Nervous system disorders Headache 
Gastrointestinal disorders 
Nausea, vomiting, diarrhoea, dyspepsia, 
abdominal pain 
Skin and subcutaneous tissue disorders 
Periorbital oedema,  
dermatitis /eczema /rash 
Musculoskeletal, connective tissue  
and bone disorders 
Muscle spam and cramps, musculoskeletal 
pain including arthralgia 
General disorders and 
Administration site conditions 
Fluid retention and oedema, fatigue 
Table 4. Very common (>1/10) adverse reactions with imatinib mesylate (Reid et al., 2005) 
2. Gastrointestinal stromal tumours of the rectovaginal septum 
GISTs located out of the gastrointestinal tract (Extragastrointestinal stromal tumors, EGISTs) 
are very uncommon; and those that arise in the rectovaginal septum are highly infrequent 
entities, that pose a challenge due to the lack of diagnostic suspicious (Ceballos et al., 2004; 
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Hellan et al., 2006; Lam et al., 2006; Marcos et al., 2010; Mussi et al., 2008; Nagase et al., 2007; 
Nasu et al., 2004; Takano et al., 2006; Tooru et al., 2001; Valera et al., 2008; Weppler et al., 
2005; Zang et al., 2009).  
The main differential diagnosis of EGISTs of the vagina and rectovaginal septum is 
leiomyoma and leiomyosarcoma. Like GISts, both leiomyoma and leiomyosarcoma are rare 
primary lesions of the vagina. Histologically, leiomyomas and leiomyosarcomas are usually 
composed of spindle cells that are arranged in fascicles. In contrast to GISTs, which have 
very fibrillary, pale pink cytoplasm, smooth muscle tumors have dense, brightly 
eosinophilic cytoplasm. In addition, leiomyosarcomas tend to exhibit pleomorphism, which 
is unusual in GIST; smooth muscle tumors are immunoreactive for smooth muscle actin and 
desmin and are negative for kit (CD117). Like GISTs, smooth muscle tumors can be positive 
for CD34. Epithelioid smooth muscle tumors can mimic both epithelioid GIST and 
carcinoma, which are the most likely soft tissue neoplasm to arise in this location. 
Carcinomas are usually strongly positive for cytokeratins, whereas GISTs rarely express this 
antigen. Nerve sheath tumors, especially schwannomas are diffusely and strongly positive 
for S-100 protein and negative for kit. Aggressive angiomyxoma is rare but tends to occur in 
the deep soft tissues of the vulva and vagina. In contrast to GIST, these lesions are always 
paucicellular, contain myxoid stroma and a prominent vascular pattern, are positive for 
actine, desmin, estrogen receptor, and progesterone receptor, and negative for kit. 
Angiomyofibroblastoma is another spindle cell lesion that enters into the differential 
diagnosis. They are typically located in the superficial soft tissues and are variably cellular 
with a prominent vascular pattern. They are negative for kit and positive for actin, desmin, 
estrogen receptor and progesterone receptor. Also, dermatofibrosarcoma protuberans can 
arise in the vulvovaginal region; they are uniformly positive for CD34, but can be 
distinguished from GIST because are negative for kit.  
Because of their malignant potential and recent advances in the management of GISTs 
with imatinib mesylate (Gleevec™) (De Matteo et al., 2007; Park et al., 2008; Verma et al., 
2009), it is imperative that these tumors are diagnosed correctly despite of the similarity in 
their structure and size. Conventional radiotherapy and chemotrapy are useless in the 
treatment of these tumors, thus this fact makes more important the misdiagnosis of these 
masses.  
However, the current definitive treatment for GIST, including EGIST, is surgical. 
In this chapter, we describe a recent case of EGIST located in the rectovaginal septum, and a 
rewiev of the recent literature in this field. 
2.1 Case report 
We report the case of a 75-year-old woman with a GIST tumor in the rectovaginal septum. 
She consulted because of unpleasant feelings in the vagina and constipation that had started 
few months ago. Colonoscopy (Fig. 1.) revealed a probably submucosal tumor of 4cm in the 
anterior wall of the lower rectum, but it could not confirm the origin (gynecological or 
gastrointestinal). The patient was admitted in our Department for close examination and 
eventual treatment.  
During the physical examination we saw a tumour of about 5 cm that stunned in the 
posterior wall of the vagina; pelvic exmination revealed (Fig. 2.) a 5cm hard, well-
circumscribed heterogeneous tumor, with a clear border in the rectovaginal space. 
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Fig. 1. Colonoscopy: Probably submucosal tumor of 4cm in the anterior wall of the lower 
rectum. 
 
 
Fig. 2. Pelvic examination revealed a mass between rectum and vagina. 
The transvaginal ultrasound showed a normal atrophic internal genitalia; and a tumor well-
delimited of about 4-5 cm; the mass appearance was solid with high vascularization. 
Nuclear magnetic resonance imaging (NMRI) from the abdomen and pelvis was performed, 
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and it showed (Fig. 3, 4 and 5.) the origin of the tumor in the anterior wall of the lower 
rectum. Tumor markers as carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP) and 
CA 19.9 were negative.  
 
 
Fig. 3. NMRI that shows the probably origin of the tumor in the anterior wall of the lower 
rectum. 
 
 
Fig. 4. Another image of NMRI that shows the location of the mass.  
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Fig. 5. A transversal section image of NMRI. It shows the mass between vagina and rectum. 
Transvaginal biopsy was performed and the specimen was histologically diagnosed as 
gastrointestinal stromal tumour (c-Kit +) of intermediate risk of malignancy. 
A transvaginal tumor enucleation was performed with the colaboration of the Department 
of Surgery, and also perineal reconstruction was done (Fig. 6, 7, 8 and 9).  
 
 
Fig. 6. A transvaginal excision of the tumor was performed. 
www.intechopen.com
 
Gastrointestinal Stromal Tumor 
 
98
 
 
Fig. 7. The tumor was fragile and ruptured during the operation. 
 
 
Fig. 8. A perineal reconstruction was also done. 
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Fig. 9. Final result of the surgery. 
The final histological study revealed a gastrointestinal stromal tumour of high risk of 
malignancy (Fig. 10, 11 and 12) (16 mitotic figures per 50 high power fields, HPF), composed 
of fascicles of spindle cells with elongated nuclei, fine chromatin, and abundant pale pink, 
fibrillary cytoplasm. Tumor size and margins could not be evaluated because it had been 
fragmented during the surgical excision, so because of the high probability of an incomplete  
 
 
Fig. 10. Fascicles of spindle cells with elongated nuclei, fine chromatin, and abundant pale 
pink, fibrillary cytoplasm. 
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surgey, adyuvant treatment with imatinib mesylate was established without important 
toxicity (Gleevec™, 400mg per day in an oral dose). After one year following this treatment, 
the patient was disease free and now, 3 years later, is following rutinary controls with no 
evidence of disease. 
 
 
Fig. 11. Original magnification, x 400.  
 
 
Fig. 12. Inmunohistochemical finding of the tumor cells. Tumor cells show strong and 
diffuse positivity for immunoreactive c-kit (original magnificaction, x 400) 
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2.2 Discusion 
EGISTs comprises about 5-7% of all GISTs. The majority of them have involved the 
mesentery, omentum, and retroperitoneum. Only eleven cases of them presenting as a 
vaginal mass have been reported previously from 2004 (Table 5). Because EGIST locates in 
the pelvic cavity, particularly adjacent to the female genital tract, the patient’s chief 
complaints may be compression to local organs leading to symptoms such as urinary 
frequency and constipation, or a mass with no symptoms. This coincides with the case we 
presented, in wich the main symptom was a sensation of vaginal mass and constipation. 
Other alterations that appear with more frequency as a vaginal mass are the cyst (Gartner's 
duct cysts, Mullerian cysts, bartholin's gland cysts) or recto-vaginal septum endometriosis. 
The age of diagnosis, 75 years is the elderly of the cases reported. In the eleven cases 
published the median age was 55.  
The combined vaginal and rectal examination is essential in the diagnosis of recto-vaginal 
masses to determine the size, mobility and consistency of the tumor. In our case we found a 
soft, cystic, multi-lobed and not fixed tumor, but in other reported cases, the consistency 
was hard, that may be related to the size and degree of malignancy.  
Transvaginal ultrasound is the most widely used imaging test to complete the diagnosis. A 
solid mass with low eco levels, similar to the uterine fibroid, is the most characteristic 
ultrasonographic data. NMRI and CT scans can help to determine the origin, size and 
relationships of the mass and the overall assessment of the pelvis. In our case, NMRI 
confirmed the origin of mass in the wall of the rectum. 
Histollogically, EGIST often presents as spindle cells and therefore might be excluded from 
the differential diagnosis of spindle-cell neoplasms and could be confused with the more 
common leiomyoma or leiomyosarcoma (Lam et al., 2006, Mettinen et al., 2001). Some 
authors reported that immunohistochemistry with antibodies against c-kit protein (CD 117) 
and CD 34 is reliable and valuable for diagnosis of EGIST (Connolly et al., 2003; De Matteo 
et al., 2000; Saund et al., 2004). GIST typically expresses CD117, often CD34 and sometimes 
SMA and S-100, but its expressions vary depending on different sites.  
Since the incidence of rectal-vaginal GIST is much lower than that of GIST in the stomach or 
small intestine, the clinicopathological profiles have not yet been accurately characterised, 
and there is therefore the tendency to validate the same prognostic factors for the latter as 
for such tumors at other sites, particularly gastric GIST. The most important and easily 
applicable histological criteria for prediction of GIST are its size and mitotic rate. A rate of ≤ 
5 mitoses per 50 HPF is commonly used as a limit for a tumor with expected benign 
behaviour, and according to a large study, this can discriminate between benign and 
malignant tumors, especially gastric GIST.(Miettinen, M. et al, 1999). Tumors of 2 cm in 
diameter are generally expected to behave in a benign fashion. Tumors of 5 cm - 10 cm in 
diameter have a better prognosis tan those of > 10 cm in diameter. Degrees of cellularity and 
atipia have also been suggested as useful criteria. 
It is generally agreed that complete surgical resection with negative tumor margins is the 
principal curative procedure for primary and non-metastatic tumors, particularly for those 
at a low risk. Neoadjuvance with imatinib mesilate (Gleevec™) may enhance the resectability 
of inoperable malignant GIST and may allow for optimal surgical timing. Therapy with 
imatinib is also used in the adjuvant post-operative treatment of tumors at a high risk or in 
cases of incomplete surgical resection. In five of the eleven cases surgery was the treatment 
done as first option, in two more cases (like the one we report) tumor escision and treatment 
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with imatinib mesylate was established. Only in one case, there was evidence of metastatic 
disease, and treatment with imatinib mesylate was the therapeutic choice. In ten of the eleven 
cases reported, the diagnosis of the tumor was before evidence of metastatic disease, 
probably because the location in the rectovaginal septum affords an early detection.  
 
Author 
(publication 
year) 
Age 
(years) 
Tumor 
size 
(cm)
Treatment Mitosis 
(/50 
HPF)
Kit
(CD117) 
CD34 Outcome 
Nasu (2004)  54  8.5 Surgery  5-10  +  +  Alive and 
well 13 
months 
Ceballos 
(2004) 
 75  4.5 Surgery  12-15  +  + Recurrence 
7.5 years 
Weppler 
(2005) 
 66  8 Imatinib  >5  +  + Not 
described 
Takano 
(2006) 
 38  7 Surgery  1-2  +  + Alive and 
well 12 
months 
Lam (2006)  36  4 Not described  15  +   + Recurrence 
2 years 
Lam (2006)  48  6 Not described  12  +  + Recurrence 
10 years 
Lam (2006)  61  8 Not described  16  +  + Not 
described 
Nagase 
(2007) 
 42  3.5 Surgery  <1  +  + Alive and 
well 4 years 
Nagase 
(2007) 
 66  5 Surgery+Imatinib  2-3  +  +  Alive and 
well 6 
months 
Zang (2009)  42  8 Surgery  10  +  + Alive and 
well 6 
months 
Marcos 
(2010), the 
current case 
 75  5 Surgery+Imatinib  16  +  + Alive and 
well till 
now 
Table 5. Clinicopathologic features of eleven reported cases of EGISTs presenting as a 
vaginal mass (Zang, 2009). 
As lymph nodes metastasis occurs infrequently (<10%), extensive lymphadenectomy need 
not to be done (Miettinen, M. et al, 1999). But despite complete resection with pathologically 
confirmed negative margins, the majority of tumors recur. In the eleven published cases, 
five recurred from several months to ten years after primitive treatment. While the majority 
of patients initially benefit from tyrosine kinase inhibitors, it is now clear that resistance 
commonly develops. Indeed, the median time to progression on imatinib mesylate is 2 years 
(De Matteo et al., 2007). 
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In our case, the final histological study revealed a gastrointestinal stromal tumor of high risk 
of malignancy (16 mitotic figures per 50 high power fields). We used Gleevec™ as 
neoadjuvant therapy. The patient showed good tolerance to the drug. Evolution has been 
very favorable, almost three years have passed and our patient is alive and free of disease. 
The lack of a large series of patients under long-term follow-up observations makes it 
difficult to assess the necessary extent of surgical resection and the indication for treatment 
with imatinib. 
3. Conclusion 
In the past years there have been significant developments in the understanding of GISTs 
and their response to therapy. Many questions remain unanswered and new issues have 
arisen as the benefits of imatinib mesylate therapy are revealed. 
EGISTs that present as gynecologic masses are rare but may be more common than is 
currently recognized. Misdiagnosis may lead to an inappropriate therapy because 
conventional radiotherapy and chemotherapy are not effective in the treatment of GISTs, 
whereas imatinib mesylate (Gleevec™) has a proven role in managing these tumors. Thus, it is 
important and necessary to consider EGISTs in the differential diagnosis of mesenchymal 
neoplasms in the vulvovaginal-rectovaginal septum. The most common symptom is due to 
compression of adjacent organs, discomfort, feeling of lump, dyspareunia or constipation 
The differential diagnosis is done with leiomyomas and vaginal cysts (Gartner's duct cysts, 
Mullerian cysts, bartholin's gland cysts). GIST typically expresses CD117, often CD34 and 
sometimes SMA and S-100, leading to the definitive diagnosis in the biopsy samples. The 
prognosis is determined by the size and mitotic count. Treatment relies on surgical excision 
of the tumor, and imatinib mesylate has shown efficacy as neoadjuvant and adjuvant 
monotherapy. 
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